Glytuzumab

N/A

Report date: 2025/11/21 17:15:32

Base Information

Drug NameGlytuzumab

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Nuclides > Gallium > 68GaRadiation-emitting products > Radionuclide Drug Conjugates +[6]

Mechanisms of ActionSingle-photon emission-computed tomography enhancersGlypican-1 antagonistsWnt signalling pathway inhibitors

TargetsGlypican-1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesGlytherix

China Registration ClassN/A

Develop Information

Active CompaniesGlytherix

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A